Evidence map›Paper›PMID 42592083›Full record

ArticleiScience2026

Tunable universal OR-gated CAR T cells for AML.

Menna Y Siddiqui, Jingyao Chen, Joey Zhuoying Huang, Madeline Loffredo, Seunghee Lee, Han Deng, Yongshuai Li, Nelia Leemans, Tim Lu, Brian S Garrison and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Menna Y SiddiquiDepartment of Biomedical Engineering and Biological Design Center, Boston University, Boston, MA, USA.
Jingyao ChenDepartment of Biomedical Engineering and Biological Design Center, Boston University, Boston, MA, USA.
Joey Zhuoying HuangDepartment of Biomedical Engineering and Biological Design Center, Boston University, Boston, MA, USA.
Madeline LoffredoDepartment of Materials Science and Engineering, Boston University, Boston, MA, USA.
Seunghee LeeDepartment of Biomedical Engineering and Biological Design Center, Boston University, Boston, MA, USA.
Han DengSenti Biosciences, South San Francisco, CA, USA.
Yongshuai LiSenti Biosciences, South San Francisco, CA, USA.
Nelia LeemansSenti Biosciences, South San Francisco, CA, USA.
Tim LuSenti Biosciences, South San Francisco, CA, USA.
Brian S GarrisonSenti Biosciences, South San Francisco, CA, USA.
Marcela Guzmán AyalaSenti Biosciences, South San Francisco, CA, USA.
Nicholas W FrankelSenti Biosciences, South San Francisco, CA, USA.
Wilson W WongDepartment of Biomedical Engineering and Biological Design Center, Boston University, Boston, MA, USA.

Funding

Precise tumor targeting with logic CAR circuitsU01CA265713 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2021 to 2025
$2.5M
In Vivo Imaging Analysis System - Xenogen IVIS SpectrumS10RR024523 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GERSTENFELD, LOUIS CHARLES · 2008 to 2008
$350k
Engineering CAR T Cells to Establish Stable Mixed Chimerism in Allogeneic TransplantationF31HL162477 · NHLBI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI SIDDIQUI, MENNA YAMANY · 2022 to 2022
$28k
NCI NIH HHS U01 CA265713NCRR NIH HHS S10 RR024523NHLBI NIH HHS F31 HL162477
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is characterized by antigen heterogeneity and poor prognosis. Here, to tackle the heterogeneity of AML, we combined FLT3 with CD33 in a combinatorial OR-gate approach using our split, universal, programmable (SUPRA) chimeric antigen receptor (CAR) platform. The split platform affords tunability over activation levels and multiplexed targeting. We characterized the specificity and sensitivity of different SUPRA CAR adapters for each target across a panel of target cell lines. Our results demonstrate that this CAR system can effectively target two antigens with equivalent efficacy to conventional CARs while reducing the engineering burden of designing CAR T cells against multiple antigens. Furthermore, we can characterize an effective dose range where off-target cytotoxicity against hematopoietic stem and progenitor cells is minimized. Our SUPRA OR gate has the potential to provide an effective and safer solution to treating AML.

Indexed as

AMLCAROR gateuniversal

Identifiers

PMID42592083
PMCPMC13463802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.